АНАЛИЗ ГИНЗЕНОЗИДОВ В КОРНЯХ ЖЕНЬШЕНЯ НАСТОЯЩЕГО (PANAX GINSENG), ИНТРОДУЦИРОВАННОГО В ЦЕНТРАЛЬНОМ БОТАНИЧЕСКОМ САДУ НАН БЕЛАРУСИ

For the first time, a detailed study of the qualitative and quantitative composition of ginsenosides in the Panax ginseng roots was carried out with the help of high-performance liquid chromatography combined with mass spectrometry (HPLC-MS). The plants were introduced into the conditions of the Republic of Belarus at the experimental plot of the Central Botanical Garden of the National Academy of Sciences of Belarus. It was found that in the examined roots, all basic neutral glycosides of ginseng (ginsenosides Rb1, Rc, Rb2/Rb3, Rd, Rf, Rg1 and Re), as well as their malonylated derivatives (malonylginsenosides Rb1, Rc, Rb2/Rb3, Rd, Rg1 and Re) and some “minor” ginsenosides (20-gluco-ginsenoside Rf, notoginsenosides R1 and R2, isomers of malonyl-ginsenosides Rb1 and Rd) are present. The research also showed that different parts of the P. ginseng roots differ significantly in a total content of ginsenosides: for the main root, this parameter was 3.3 % of dry mass, and for the lateral roots – 7.8 % of dry mass.Впервые с помощью высокоэффективной жидкостной хроматографии, совмещенной с массспектрометрией (ВЭЖХ-МС) проведено подробное изучение качественного и количественного состава гинзенозидов в корнях женьшеня настоящего (P. ginseng C. A. Mey.), интродуцированного в условиях Республики Беларусь (опытный участок ЦБС НАН Беларуси). Установлено, что в изученных корнях присутствуют все основные нейтральные гликозиды женьшеня (гинзенозиды Rb1, Rc, Rb2/Rb3, Rd, Rf, Rg1 и Re), а также их малонилированные производные (малонил-гинзенозиды Rb1, Rc, Rb2/Rb3, Rd, Rg1 и Re) и некоторые «минорные» гинзенозиды (20-глюко-гинзенозид Rf, нотогинзенозиды R1 и R2, изомеры малонил-гинзенозидов Rb1 и Rd). Показано также, что разные части корней P. ginseng существенно отличаются по суммарному содержанию гинзенозидов: для основного корня этот параметр составил 3,3 % от сухой массы, а для боковых корней – 7,8 % от сухой массы

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Analysis of the dynamics of <i>Neisseria gonorrhоeaе</i> resistance to antimicrobial drugs in the Russian Federation for the period 2005–2021

Background. Neisseria gonorrhoeae can rapidly develop resistance to antimicrobial agents due to innate mechanisms for the acquisition of antimicrobial resistance genes. Because of the rapid formation of resistance mechanisms of N. gonorrhoeae to the antimicrobial agents used in gonococcal therapy, the risk of incurable forms of the disease is high. The purpose of the study is to to summarize the results of RU-GASP over a 16-year period and assess the trends of N. gonorrhoeae resistance to antimicrobials used in the regimens of antibiotic therapy of gonococcal infection in Russia. Materials and methods. Study Objective. The study included 5356 isolates of N. gonorrhoeae received from January 2005 to December 2021 in State Scientific Center of Dermatovenerology and Cosmetology, Moscow of the Ministry of Health of Russia under the RU-GASP program from specialized medical organizations of dermatovenerological profile of 37 subjects of the Russian Federation. Primary identification of N. gonorrhoeae was performed using bacterioscopic and bacteriological methods. The cultures identified as N. gonorrhoeae were frozen in a cryogenic medium and transported to SSCDC. Received cultures were verified by biochemical criteria on a VITEK 2 Compact analyzer. For cultures identified as N. gonorrhoeae with less than 99% probability, a time-of-flight ionization mass spectrometer MALDI Microflex (Bruker Daltonics GmbH, Germany) was used for mass spectrometric analysis. Antimicrobial susceptibility testing. Sensitivity testing of N. gonorrhoeae to six antimicrobials penicillin, spectinomycin, ceftriaxone, tetracycline, azithromycin and ciprofloxacin was performed by serial dilution in agar with determination of minimum suppressive concentrations (MSC, mg/L). N. gonorrhoeae sensitivity to antibacterial agents was evaluated according to EUCAST criteria (The European Committee on Antimicrobial Susceptibility Testing, 2022, http://www.eucast.org). Results. The study showed the absence of significant changes in the ratio of sensitive and resistant to the action of antimicrobial drugs strains of N. gonorrhoeae that is a consequence of the effectiveness of the RU-GASP program, which allowed to exclude in time from therapeutic use the drugs for which a high proportion of the identified resistant strains was observed. Conclusion. Analysis of RU-GASP results over a 16-year period confirms the use of third-generation cephalosporins (Ceftriaxone, Cefixime) as the drugs of choice for therapy of gonococcal infection, and the aminocyclic antibiotic spectinomycin as an alternative drug. The continued evolution of the molecular mechanisms of antibiotic resistance of N. gonorrhoeae dictates the need to continue the RU-GASP program

Suspension Cell Culture of <i>Dioscorea deltoidea</i>—A Renewable Source of Biomass and Furostanol Glycosides for Food and Pharmaceutical Industry

Dioscorea deltoidea is a medicinal plant valued for its high content of steroidal glycosides (SG)—bioactive compounds with cardioprotective and immunomodulation actions, also used to treat reproductive system disorders. To overcome the limitations of natural resources of this species, a suspension cell culture of D. deltoidea was developed as a renewable and ecologically sustainable source of raw biomass and SG. Cell culture demonstrated stable and intensive growth in the laboratory (20 L) and industrial (630 L) bioreactors operated under a semi-continuous regime (specific growth rate 0.11–1.12 day−1, growth index 3.5–3.7). Maximum dry weight accumulation (8.5–8.8 g/L) and SG content (47–57 mg/g DW) were recorded during the stationary phase. Bioreactor-produced cell biomass contained inorganic macro (K, Ca, Mg, Na) and micro (Zn, Mn, Fe, B, Al, Cu, Cr, Se, Co, Ni) elements in concentrations within the safe range of dietary recommendations. Acute toxicity test showed no or insignificant changes in organ weight, hematological panel and blood biochemistry of laboratory animals fed with 2000 and 5000 mg/kg dry biomass. The results suggest that cell culture of D. deltoidea grown in bioreactors has great potential to be used as functional foods and a component of specialized dietary supplements in complex therapy of reproductive system disorders and mineral deficiency